SK Biopharmaceuticals (326030) rose more than 2% intraday on the 26th, showing strength. Behind the stock's gains is a securities firm analysis that the trend of expanding prescriptions for Xcopri, the company's flagship epilepsy treatment, is continuing.

On this day, SK Biopharmaceuticals traded at 86,200 won, up 1,800 won from the previous trading day, a gain of about 2.13%.

On the 25th, Hungkuk Securities issued a 'BUY' rating on SK Biopharmaceuticals and presented a target price of 140,000 won. Based on the previous day's closing price, the target price represents an upside of about 62.0% from the share price at that time.

Hungkuk Securities cited the expansion of prescriptions for Xcopri, sold in the U.S. market, as the company's core growth driver. The firm judged that expectations for future revenue growth can be maintained, given that the prescription growth trend continues steadily.

Xcopri is a novel epilepsy drug independently developed by SK Biopharmaceuticals, which has built a direct sales system in the U.S. market to commercialize it. It is regarded as a key product that determines the company's performance, as increased prescription volumes can translate into revenue expansion and improved profitability.

For new drug developers, not only clinical outcomes but also the actual pace of prescription growth after commercialization significantly affect corporate value. If Xcopri broadens its prescription base in the U.S. market, SK Biopharmaceuticals' earnings structure has room to improve gradually.

The market views future prescription growth rates for Xcopri, U.S. revenue growth, and the development status of new indications and follow-up pipeline assets as key variables that will determine the stock's direction.

[Stock prices can experience greatly expanded volatility depending on domestic and overseas market trends, industry supply and demand, corporate earnings and disclosures, commodity prices, and policy changes. There is a possibility of sharp short-term swings due to shifts in investor sentiment, so future direction should not be determined solely by intraday fluctuations. Please comprehensively check official disclosures, earnings, business progress, and market supply and demand. This article is not intended to recommend the purchase or sale of specific stocks or to guarantee investment returns. This article was written with AI assistance.]